ArticleFrontiers in immunology2024

Neoadjuvant immunochemotherapy improves clinical outcomes of patients with esophageal cancer by mediating anti-tumor immunity of CD8+ T (Tc1) and CD16+ NK cells.

Yunlong He et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.